← Leaderboards
Andrea Bonetto
University Of Colorado Denver
$3,744,375
Attributed
$3,744,375
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $871.4K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,744,375 · 3
By mechanism
R01$3,371,145 · 2
R21$373,230 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Patti J Thureen$2,913,434
- Stephanie R Wesolowski$5,254,972
- William W Hay$11,044,056
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMuscle FormAtrophicDiagnosisMuscleIn VivoQuality Of LifeMuscular AtrophyTumorAffectExperimental ModelsIn VitroMuscle FibersSymptomsGrowthCachexiaCancer CachexiaAnimalsBindingImplantBone ResorptionBone MassBone LossCancer Survivor
Grant awards (10)
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia$399,447
R01 · FY2025 · AR · contact PI
Targeting RANKL for the treatment of muscle and bone defects in cachexia$399,360
R01 · FY2025 · AR · contact PI
Targeting RANKL for the treatment of muscle and bone defects in cachexia$421,078
R01 · FY2024 · AR · contact PI
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia$408,037
R01 · FY2024 · AR · contact PI
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia$429,999
R01 · FY2023 · AR · contact PI
Targeting RANKL for the treatment of muscle and bone defects in cachexia$458,716
R01 · FY2022 · AR · contact PI
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia$412,676
R01 · FY2022 · AR · contact PI
Targeting RANKL for the treatment of muscle and bone defects in cachexia$441,832
R01 · FY2021 · AR · contact PI
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia$169,650
R21 · FY2015 · CA · contact PI
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia$203,580
R21 · FY2014 · CA · contact PI